8-K: Allakos Inc. Faces Nasdaq Delisting Threat Due to Low Share Price

Allakos Inc. received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Summary

• Allakos Inc. received a letter from Nasdaq on March 12, 2025, indicating that it does not meet the minimum bid price of $1.00 per share required for continued listing on the Nasdaq Global Select Market.
• This non-compliance is based on the closing bid price of the company's common stock for the 30 consecutive business day period between January 27, 2025, and March 11, 2025.
• Allakos has been granted a compliance period until September 8, 2025, to regain compliance.
• To regain compliance, the company's shares must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the compliance period.
• If the company fails to regain compliance by September 8, 2025, it may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
• To qualify for the second compliance period, Allakos would need to submit a transfer application, pay an application fee, meet the continued listing requirement for the market value of its publicly held shares, and all other initial listing standards for Nasdaq, with the exception of the bid price requirement.
• The company would also need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.
• There is no assurance that Allakos will be eligible for the second compliance period or that Nasdaq will grant the company's request for continued listing.
• Allakos intends to actively monitor its stock price and evaluate options to resolve the deficiency.
• There is no assurance that the company will be able to regain or maintain compliance with the minimum bid price requirement or any other Nasdaq listing standard.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating potential financial distress and uncertainty about the company's future.

Positives

• Allakos has been granted a compliance period to regain compliance with Nasdaq listing rules.
• The company may be eligible for an additional compliance period by transferring to the Nasdaq Capital Market.
• Allakos is actively monitoring its stock price and evaluating options to resolve the deficiency.

Negatives

• Allakos's stock price has fallen below the minimum bid price required for continued listing on the Nasdaq Global Select Market.
• There is no assurance that the company will be able to regain or maintain compliance with the minimum bid price requirement.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.

Risks

• Failure to regain compliance with Nasdaq listing rules could result in delisting.
• Delisting could negatively impact the company's stock price and investor confidence.
• There is no guarantee that Allakos will be eligible for a second compliance period.
• The company may need to implement a reverse stock split to regain compliance, which could further dilute shareholder value.

Future Outlook

The company intends to actively monitor the closing bid price of its shares of common stock during the Compliance Period and may, if appropriate, evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement.

Industry Context

Delisting notices are not uncommon for biotech companies, especially those with clinical trial setbacks or financial difficulties. Many companies in similar situations explore options like reverse stock splits or mergers to regain compliance.

Comparison to Industry Standards

• Many biotech companies facing similar delisting threats consider reverse stock splits, as seen with companies like Cassava Sciences and Ocugen.
• Another common strategy is to seek a merger or acquisition to boost the stock price, similar to what happened with Immunomedics when it was acquired by Gilead Sciences.
• Compared to the average time it takes for companies to regain compliance, Allakos's 180-day period is standard.

Stakeholder Impact

• Shareholders face the risk of further stock price decline and potential delisting.
• Employees may experience uncertainty about the company's future.
• Creditors may become more cautious about extending credit to the company.

Next Steps

• Allakos will monitor its stock price.
• Allakos will evaluate options to resolve the deficiency and regain compliance.
• Allakos may consider a reverse stock split.

Key Dates